Status:
COMPLETED
Comparing Angioplasty and DES in the Treatment of Subjects With Ischemic Infrapopliteal Arterial Disease
Lead Sponsor:
Cordis US Corp.
Conditions:
Peripheral Arterial Diseases
Eligibility:
All Genders
18-85 years
Phase:
PHASE4
Brief Summary
The primary objective of this study is to compare the performance of the CYPHER SELECTTM + Sirolimus-eluting Balloon-expandable Coronary and Infrapopliteal Stent over balloon angioplasty in de novo an...
Detailed Description
This is a multicenter, prospective, randomized study to be conducted in 18 centers in Europe. A total of 200 subjects will be entered into the study and will be randomized on a 1:1 basis to either bal...
Eligibility Criteria
Inclusion
- Subject must be \>= 18 and \<= 85 years old;
- Female of childbearing potential must have a negative pregnancy test within 10 days prior to index procedure and utilize reliable birth control until completion of the 12-month angiographic evaluation;
- Clinical diagnosis of symptomatic critical limb ischemia as defined by Rutherford 3, 4, or 5;
- Single treatment of de novo or restenotic (after PTA only) lesion(s) in the tibioperoneal trunk, anterior and/or posterior tibial and/or peroneal artery;
- A maximum of 2 vessels in 1 limb may be treated in the study, each vessel for only 1 target lesion, resulting in at single risk target lesion(s); In case 1 target lesion is located in the Tibioperoneal trunk, the 2nd target lesion (if applicable) can only be located in the anterior tibial artery; Additional non-target lesion(s) in remaining non-target vessel(s) can be treated at the physician's discretion by means of balloon dilation (± bail-out stenting);
- The sum of the total length of both target lesions can be maximum 120 mm;
- In total a maximum of 4 stents may be implanted to fully cover the maximum of 2 target lesions per subject;
- Target vessel is \>= 2.5 and \<= 3.5 mm in diameter (visual estimate);
- Target lesion stenosis is \>70% diameter stenosis (visual estimate);
- Guidewire must be across the first (if applicable) target lesion and located intraluminally within the distal vessel before study randomization;
- Willing to comply with the specified follow-up evaluation;
- Written informed consent prior to any study procedures.
Exclusion
- Significant (\>50%) stenoses distal to the target lesion that might require revascularization, or impede runoff;
- Angiographic evidence of thrombus within target vessel;
- Thrombolysis within 72 hours prior to the index procedure;
- Lesions not suitable for stenting;
- Lesions (defined as stenosis \> 75%) in the common or external iliac, common or superficial femoral and popliteal artery. However, intervention in TASC A and B lesions (max. 15cm) to restore adequate blood flow, in the same index procedure is allowed. This intervention must be prior to the treatment of the study lesion(s) and successful;
- Lesions located at the bifurcation requiring treatment of both branches (1 in main branch and 1 in side branch);
- Required stent placement across or within 1 cm of the knee joint; in an artery subject to external compression, or in an artery directly subject to movement of the ankle or knee joint;
- Prior stent(s) within the target vessel(s);
- Aneurysm in the SFA or popliteal artery;
- Requiring popliteal arterial access;
- Concomitant hepatic insufficiency, thrombophlebitis, deep venous thrombus, coagulation disorder or receiving immunosuppressant therapy;
- Recent MI or stroke \< 30 days prior to the index procedure;
- Coronary intervention \< 30 days prior to the index procedure;
- Life expectancy less than 12 months;
- Known or suspected active infection at the time of the index procedure, excluding an infection of a lower extremity wound of the target limb;
- Impaired renal function (creatinine \> 2.5 mg/dl);
- Known or suspected allergies or contraindications to aspirin, clopidogrel bisulfate (PlavixÒ) and ticlopidine (Ticlidâ), heparin, stainless steel or contrast agent;
- The subject is currently taking Coumarin / Warfarin which, in the opinion of the investigator, interferes with the subject's participation in the study;
- Any significant medical condition which, in the investigator's opinion, may interfere with the subject's optimal participation in the study;
- The subject is currently participating in another investigational drug or device study that has not completed the primary endpoint or that clinically interferes with the endpoints of this study.
Key Trial Info
Start Date :
March 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2011
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT00640770
Start Date
March 1 2008
End Date
January 1 2011
Last Update
March 15 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Universität Leipzig - Herzzentrum
Leipzig, Germany, 04289